[go: up one dir, main page]

WO2009011285A1 - ヘテロアリールベンゼン化合物 - Google Patents

ヘテロアリールベンゼン化合物 Download PDF

Info

Publication number
WO2009011285A1
WO2009011285A1 PCT/JP2008/062514 JP2008062514W WO2009011285A1 WO 2009011285 A1 WO2009011285 A1 WO 2009011285A1 JP 2008062514 W JP2008062514 W JP 2008062514W WO 2009011285 A1 WO2009011285 A1 WO 2009011285A1
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
heteroarylbenzene
hyperlipemia
hypertriglyceridemia
arteriosclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/062514
Other languages
English (en)
French (fr)
Inventor
Hiroki Umemiya
Masato Takahashi
Masahiro Bohno
Kenichi Kawabe
Shinichi Shirokawa
Takayuki Nagatsuka
Shigetada Sasako
Rui Satou
Shin Itoh
Takanori Shimizu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissan Chemical Corp
Taisho Pharmaceutical Co Ltd
Original Assignee
Nissan Chemical Corp
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2007292604A external-priority patent/JP2010215511A/ja
Application filed by Nissan Chemical Corp, Taisho Pharmaceutical Co Ltd filed Critical Nissan Chemical Corp
Publication of WO2009011285A1 publication Critical patent/WO2009011285A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

　式（１） （式（１）中、 　ＡはＮ又はＣＨを示し、 　Ｒ１は水素原子、又はＣ１－８アルキル基を示し、 　Ｒ２ａ及びＲ２ｂは水素原子、ハロゲン原子、又はＣ１－６アルキル基からなる群より同一若しくは異なって選ばれる基を示し、 　Ｑは置換又は無置換のフェニル基、ベンジル基、ナフチル基、テトラヒドロナフチル基、又はＣ３－１０シクロアルキル基等を示し、 　ｍは０又は１を示し、 　ｎは０又は１を示し、 　Ｘは－Ｏ－、又は－ＮＲ３－を示し、 　Ｙは置換又は無置換のＣ１－８アルキレン基等を示す。）で表されるヘテロアリールベンゼン化合物、該化合物の互変異性体、立体異性体、若しくはその薬学的に許容される塩、又はそれらの溶媒和物は、ＤＧＡＴ１阻害作用により改善しうる疾患又は状態、例えば、肥満症、高脂血症、高トリグリセライド血症、脂質代謝異常疾患、糖尿病、動脈硬化症、または、肥満に起因する高脂血症、高トリグリセライド血症、脂質代謝異常疾患、糖尿病、動脈硬化症、もしくは、高血圧症を予防若しくは治療するための医薬に好適である。
PCT/JP2008/062514 2007-07-13 2008-07-10 ヘテロアリールベンゼン化合物 Ceased WO2009011285A1 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007-185047 2007-07-13
JP2007185047 2007-07-13
JP2007-292604 2007-11-09
JP2007292604A JP2010215511A (ja) 2007-11-09 2007-11-09 ヘテロアリールベンゼン化合物

Publications (1)

Publication Number Publication Date
WO2009011285A1 true WO2009011285A1 (ja) 2009-01-22

Family

ID=40259621

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/062514 Ceased WO2009011285A1 (ja) 2007-07-13 2008-07-10 ヘテロアリールベンゼン化合物

Country Status (2)

Country Link
TW (1) TW200918053A (ja)
WO (1) WO2009011285A1 (ja)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7749997B2 (en) 2005-12-22 2010-07-06 Astrazeneca Ab Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors
US7795283B2 (en) 2004-12-14 2010-09-14 Astrazeneca Ab Oxadiazole derivative as DGAT inhibitors
WO2010107765A1 (en) 2009-03-18 2010-09-23 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
WO2010108051A2 (en) 2009-03-20 2010-09-23 Ligand Pharmaceuticals Inhibitors of diacylglycerol o-acyltransferase 1(dgat-1) and uses thereof
US7879850B2 (en) 2007-09-28 2011-02-01 Novartis Ag Organic compounds
WO2011022473A1 (en) * 2009-08-19 2011-02-24 Ambit Biosciences Corporation Biaryl compounds and methods of use thereof
WO2011078102A1 (ja) * 2009-12-22 2011-06-30 第一三共株式会社 新規フェノキシピリミジン誘導体
US8084478B2 (en) 2006-05-30 2011-12-27 Asstrazeneca Ab Substituted 5- phenylamino- 1, 3, 4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase
WO2012165398A1 (ja) * 2011-05-30 2012-12-06 第一三共株式会社 シクロアルキルオキシビアリール型化合物
JP2013525377A (ja) * 2010-04-23 2013-06-20 サイトキネティクス・インコーポレーテッド ある種のアミノ−ピリミジン、その組成物、及びそれを用いるための方法
JP2013538808A (ja) * 2010-09-03 2013-10-17 ピラマル エンタープライジーズ リミテッド Ｄｇａｔ１阻害剤としての複素環式化合物
WO2013187496A1 (ja) 2012-06-15 2013-12-19 田辺三菱製薬株式会社 芳香族複素環化合物
US8653131B2 (en) 2008-08-22 2014-02-18 Baxter Healthcare S.A. Polymeric benzyl carbonate-derivatives
US8835451B2 (en) 2006-03-31 2014-09-16 Novartis Ag Compounds
US9302996B2 (en) 2010-12-17 2016-04-05 Mitsubishi Tanabe Pharma Corporation Continuous arycyclic compound
JP2016523902A (ja) * 2013-06-27 2016-08-12 エルジー・ライフ・サイエンシーズ・リミテッドＬＧ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． Ｇｐｒ１２０アゴニストとしてのビアリール誘導体
JP2018501269A (ja) * 2014-12-24 2018-01-18 エルジー・ケム・リミテッド Ｇｐｒ１２０アゴニストとしてのビアリール誘導体
US9994528B2 (en) 2010-04-23 2018-06-12 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
US10076519B2 (en) 2010-04-23 2018-09-18 Cytokinetics, Inc. Substituted pyridazines as skeletal muscle modulators
WO2021249228A1 (zh) 2020-06-08 2021-12-16 四川百利药业有限责任公司 一种带有高稳定性亲水连接单元的喜树碱类药物及其偶联物
WO2021255089A1 (en) 2020-06-19 2021-12-23 Bayer Aktiengesellschaft 1,3,4-oxadiazole pyrimidines and 1,3,4-oxadiazole pyridines as fungicides
WO2023083381A1 (zh) 2021-11-15 2023-05-19 成都百利多特生物药业有限责任公司 双特异性抗体-喜树碱类药物偶联物及其医药用途
WO2023098889A1 (zh) 2021-12-03 2023-06-08 成都百利多特生物药业有限责任公司 抗人Trop2抗体-喜树碱类药物偶联物及其医药用途
WO2024067477A1 (zh) 2022-09-26 2024-04-04 成都百利多特生物药业有限责任公司 抗cd33抗体和抗cd33抗体-药物偶联物及其用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013056679A1 (en) * 2011-10-21 2013-04-25 Beijing Hanmi Pharmaceutical Co., Ltd Novel heteroaryl-amino derivatives

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006045209A (ja) * 2004-07-02 2006-02-16 Sankyo Co Ltd ウレア誘導体
WO2006019020A1 (ja) * 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006045209A (ja) * 2004-07-02 2006-02-16 Sankyo Co Ltd ウレア誘導体
WO2006019020A1 (ja) * 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795283B2 (en) 2004-12-14 2010-09-14 Astrazeneca Ab Oxadiazole derivative as DGAT inhibitors
US7749997B2 (en) 2005-12-22 2010-07-06 Astrazeneca Ab Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors
US8017603B2 (en) 2005-12-22 2011-09-13 Astrazeneca Ab Pyrimido [4,5-B]-oxazines for use as DGAT inhibitors
US8912208B2 (en) 2006-03-31 2014-12-16 Novartis Ag (4-{4-[5-(benzooxazol-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid useful for treating or preventing conditions or disorders associated with DGAT1 activity
US8835451B2 (en) 2006-03-31 2014-09-16 Novartis Ag Compounds
US8084478B2 (en) 2006-05-30 2011-12-27 Asstrazeneca Ab Substituted 5- phenylamino- 1, 3, 4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase
US7879850B2 (en) 2007-09-28 2011-02-01 Novartis Ag Organic compounds
US8217065B2 (en) 2007-09-28 2012-07-10 Novartis Ag Organic compounds
US8962549B2 (en) 2008-08-22 2015-02-24 Baxter International Inc. Polymeric benzyl carbonate-derivatives
US8653131B2 (en) 2008-08-22 2014-02-18 Baxter Healthcare S.A. Polymeric benzyl carbonate-derivatives
WO2010107768A1 (en) 2009-03-18 2010-09-23 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
WO2010107765A1 (en) 2009-03-18 2010-09-23 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
JP2012520886A (ja) * 2009-03-18 2012-09-10 シェーリング コーポレイション ジアシルグリセロールアシルトランスフェラーゼの阻害剤としての二環式化合物
US8637507B2 (en) 2009-03-18 2014-01-28 Merck Sharp & Dohme Corp. Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
US10709718B2 (en) 2009-03-20 2020-07-14 Metabasis Therapeutics, Inc. Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof
EP3366686A2 (en) 2009-03-20 2018-08-29 Metabasis Therapeutics, Inc. Inhibitors of diacylglycerol o-acyltransferase 1 (dgat-1) and uses thereof
US10034891B2 (en) 2009-03-20 2018-07-31 Metabasis Therapeutics, Inc. Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof
US9340566B2 (en) 2009-03-20 2016-05-17 Metabasis Therapeutics, Inc. Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof
EP2805951A2 (en) 2009-03-20 2014-11-26 Metabasis Therapeutics, Inc. Inhibitors of diacylglycerol o-acyltransferase 1 (DGAT-1) and uses thereof
US8962618B2 (en) 2009-03-20 2015-02-24 Metabasis Therapeutics, Inc. Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof
WO2010108051A2 (en) 2009-03-20 2010-09-23 Ligand Pharmaceuticals Inhibitors of diacylglycerol o-acyltransferase 1(dgat-1) and uses thereof
US20130035326A1 (en) * 2009-08-19 2013-02-07 Ambit Biosciences Corporation Biaryl compounds and methods of use thereof
JP2013502429A (ja) * 2009-08-19 2013-01-24 アムビト ビオスシエンセス コルポラチオン ビアリール化合物及びその使用方法
WO2011022473A1 (en) * 2009-08-19 2011-02-24 Ambit Biosciences Corporation Biaryl compounds and methods of use thereof
WO2011078102A1 (ja) * 2009-12-22 2011-06-30 第一三共株式会社 新規フェノキシピリミジン誘導体
US10076519B2 (en) 2010-04-23 2018-09-18 Cytokinetics, Inc. Substituted pyridazines as skeletal muscle modulators
US10765624B2 (en) 2010-04-23 2020-09-08 Cytokinetics, Inc. Amino-pyrimidine skeletal muscle modulators
US11369565B2 (en) 2010-04-23 2022-06-28 Cytokinetics, Inc. Amino-pyrimidine skeletal muscle modulators
US10272030B2 (en) 2010-04-23 2019-04-30 Cytokinetics, Inc. Amino-pyrimidine skeletal muscle modulators
JP2013525377A (ja) * 2010-04-23 2013-06-20 サイトキネティクス・インコーポレーテッド ある種のアミノ−ピリミジン、その組成物、及びそれを用いるための方法
US9730886B2 (en) 2010-04-23 2017-08-15 Cytokinetics, Inc. Amino-pyrimidine skeletal muscle modulators
US9994528B2 (en) 2010-04-23 2018-06-12 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
JP2013538808A (ja) * 2010-09-03 2013-10-17 ピラマル エンタープライジーズ リミテッド Ｄｇａｔ１阻害剤としての複素環式化合物
US9975871B2 (en) 2010-12-17 2018-05-22 Mitsubishi Tanabe Pharma Corporation Continuous arycyclic compound
US9302996B2 (en) 2010-12-17 2016-04-05 Mitsubishi Tanabe Pharma Corporation Continuous arycyclic compound
WO2012165398A1 (ja) * 2011-05-30 2012-12-06 第一三共株式会社 シクロアルキルオキシビアリール型化合物
US9546155B2 (en) 2012-06-15 2017-01-17 Mitsubishi Tanabe Pharma Corporation Aromatic heterocyclic compound
US10308636B2 (en) 2012-06-15 2019-06-04 Mitsubishi Tanabe Pharma Corporation Aromatic heterocyclic compound
WO2013187496A1 (ja) 2012-06-15 2013-12-19 田辺三菱製薬株式会社 芳香族複素環化合物
JPWO2013187496A1 (ja) * 2012-06-15 2016-02-08 田辺三菱製薬株式会社 芳香族複素環化合物
US10221138B2 (en) 2013-06-27 2019-03-05 Lg Chem, Ltd. Biaryl derivatives as GPR120 agonists
JP2016523902A (ja) * 2013-06-27 2016-08-12 エルジー・ライフ・サイエンシーズ・リミテッドＬＧ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． Ｇｐｒ１２０アゴニストとしてのビアリール誘導体
JP2018501269A (ja) * 2014-12-24 2018-01-18 エルジー・ケム・リミテッド Ｇｐｒ１２０アゴニストとしてのビアリール誘導体
WO2021249228A1 (zh) 2020-06-08 2021-12-16 四川百利药业有限责任公司 一种带有高稳定性亲水连接单元的喜树碱类药物及其偶联物
WO2021255089A1 (en) 2020-06-19 2021-12-23 Bayer Aktiengesellschaft 1,3,4-oxadiazole pyrimidines and 1,3,4-oxadiazole pyridines as fungicides
WO2023083381A1 (zh) 2021-11-15 2023-05-19 成都百利多特生物药业有限责任公司 双特异性抗体-喜树碱类药物偶联物及其医药用途
WO2023098889A1 (zh) 2021-12-03 2023-06-08 成都百利多特生物药业有限责任公司 抗人Trop2抗体-喜树碱类药物偶联物及其医药用途
WO2024067477A1 (zh) 2022-09-26 2024-04-04 成都百利多特生物药业有限责任公司 抗cd33抗体和抗cd33抗体-药物偶联物及其用途

Also Published As

Publication number Publication date
TW200918053A (en) 2009-05-01

Similar Documents

Publication Publication Date Title
WO2009011285A1 (ja) ヘテロアリールベンゼン化合物
EP1736467A4 (en) NEW SULFONIC ACID AMID DERIVATIVE
WO2009020140A1 (ja) アダマンチルウレア誘導体
AU2008245082A8 (en) Aminodihydrothiazine derivatives substituted with a cyclic group
NO20054224L (no) Nye 2-pyridinkarboksamidderivater
WO2008060476A3 (en) Nitrogen-containing heterocyclic compounds and methods of use thereof
WO2007127635A3 (en) Diketo-piperazine and piperidine derivatives as antiviral agents
WO2008114817A1 (ja) 新規なアデニン化合物
WO2008108386A1 (ja) 医薬組成物
WO2007122634A3 (en) Pyrimidinediones as tyrosine kinase inhibitors
NZ590355A (en) Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
WO2008156174A1 (ja) ピラジンアミド化合物
TNSN08407A1 (en) Organic compounds
NO20093275L (no) 1,3-Dihydroimidazol-2-thione derivater som inhibitorer av dopamin-beta-hydroksylase
WO2009057784A1 (ja) 複素環化合物
MX2009006689A (es) Inhibidores viia de los factores macrociclicos utiles como anticoagulantes.
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
WO2009069736A1 (ja) 含窒素化合物
WO2007095603A3 (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
EP1790636A4 (en) Piperidin derivatives and their use
WO2009063821A1 (ja) ヘテロアリールオキシキナゾリン誘導体
MX2010001566A (es) Derivado de aminopirazolamida.
NO20052074L (no) Substituerte benzoksazinoner og anvendelser derav.
WO2004017977A3 (en) 2- (phenoxymethyl)- and 2- (phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
NO20071319L (no) Fremgangsmate for fremstilling av isotiazolderivater.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08791062

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08791062

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP